The Experts below are selected from a list of 2166 Experts worldwide ranked by ideXlab platform

Herman Adlercreutz - One of the best experts on this subject based on the ideXlab platform.

  • Risk of Cardiovascular Disease-Related and All-Cause Death According to Serum Concentrations of Enterolactone
    2020
    Co-Authors: Meri Vanharanta, Herman Adlercreutz, Sari Voutilainen, Tiina H Rissanen, Jukka T Salonen
    Abstract:

    Background: Enterolactone is a plant-derived compound that has been associated with a reduced risk of acute coronary events and cancer. Several studies have suggested that serum Enterolactone concentration may play a role as a biomarker of a diet high in fiber and vegetables. Owing to its phenolic structure, Enterolactone and its plant lignan precursors, which are converted by intestinal bacteria to Enterolactone, are potential antioxidants. Methods: The associations between serum Enterolactone level and the risk of coronary heart disease (CHD)– related, cardiovascular disease (CVD)–related, and allcause mortality were investigated in the Kuopio Ischaemic Heart Disease Risk Factor Study, which is a prospective population-based study of middle-aged Finnish men. The serum Enterolactone concentration and cardiovascular risk factors were determined in 1889 men aged 42 to 60 years. In an average follow-up of 12.2 years, 70 CHDrelated, 103 CVD-related, and 242 all-cause deaths occurred in participants free of prior CVD. Results: Multivariate analyses showed significant associations between elevated serum Enterolactone concentration and reduced risk of CHD- and CVD-related mortality, but weaker associations in relation to allcause mortality. In the Cox proportional hazards regression model adjusting for the most potent confounding factors, the risk of CHD-related (P = .03 for trend) and CVD-related (P = .04 for trend) death decreased linearly across quartiles of serum Enterolactone concentration. Conclusions: Our data suggest that a high serum Enterolactone level is associated with reduced CHD- and CVD-related mortality in middle-aged Finnish men. These results add to the evidence supporting the importance of whole grain foods, fruits, and vegetables in the prevention of premature death from CVD. Arch Intern Med. 2003;163:1099-1104

  • Serum Enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
    Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2020
    Co-Authors: Annamari Kilkkinen, Herman Adlercreutz, Jarmo Virtamo, Mikko J Virtanen, Demetrius Albanes, Pirjo Pietinen
    Abstract:

    The lignan Enterolactone, produced by the intestinal microflora from dietary precursors, has been hypothesized to protect against hormone-dependent cancers and cardiovascular diseases. We conducted a nested case-control study to examine the relationship between serum Enterolactone concentration and prostate cancer. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum collected at baseline in the alpha-Tocopherol, beta-Carotene Cancer Prevention Study from 214 men with prostate cancer diagnosed during a 6-year follow-up and from 214 controls matched by age, date of baseline blood collection, intervention group, and local study area. Mean serum Enterolactone concentration (in nmol/liter) did not differ significantly between case and control subjects [15.9 (SD, 15.2) versus 16.9 (SD, 14.9), respectively (P = 0.42)]. Odds ratios for prostate cancer risk estimated by conditional logistic regression for increasing quartiles of Enterolactone concentration were 1.00 (referent), 0.72 [95% confidence interval (CI), 0.43-1.23], 0.98 (95% CI, 0.58-1.68), and 0.71 (95% CI, 0.42-1.21). Our findings do not support the hypothesis that Enterolactone is involved in the development of prostate cancer.

  • plasma Enterolactone and risk of prostate cancer in middle aged swedish men
    European Journal of Nutrition, 2018
    Co-Authors: Peter Wallstrom, Herman Adlercreutz, Matti J. Tikkanen, Emily Sonestedt, Bo Gullberg, Hakan Olsson, Isabel Drake, Anders Bjartell, Elisabet Wirfalt
    Abstract:

    Purpose Enterolactone (ENL) is formed in the human gut after consumption of lignans, has estrogenic properties, and has been associated with risk of prostate cancer. We examined the association between plasma ENL levels and prostate cancer in a nested case–control study within the population-based Malmo Diet and Cancer cohort. We also examined the association between plasma ENL and dietary and lifestyle factors.

  • validation of ffq based assessment of dietary lignans compared with serum Enterolactone in swedish women
    British Journal of Nutrition, 2013
    Co-Authors: Alicja Wolk, José L. Peñalvo, Herman Adlercreutz, Niclas Hakansson, Jesper Lagergren, Yunxia Lu
    Abstract:

    The validity of using FFQ to assess dietary lignans is uncertain. We aimed to validate the use of FFQ for the assessment of dietary intake of lignans compared to the serum biomarker Enterolactone, the main product of dietary lignans' metabolism in human subjects. A random sample of women, aged 55–75 years, from the Swedish Mammography Cohort was selected. Information from two FFQ, the FFQ-87 (sixty-seven food items) and the FFQ-97 (ninety-three food items), and blood samples were collected. Dietary intake of lignans (secoisolariciresinol, matairesinol, lariciresinol, pinoresinol, medioresinol and syringaresinol) was assessed by the FFQ. Serum concentrations of Enterolactone were analysed by time-resolved fluoroimmunoassay. The correlation coefficient between energy-adjusted lignan intake and serum Enterolactone was estimated in crude and multivariable-adjusted models, taking into account the factors potentially influencing the serum Enterolactone. Among the 135 participants aged 55–75 years, with a mean BMI of 26·7 kg/m 2 , the average energy-adjusted intake of total lignans was 1616 ( sd 424) and 1516 ( sd 409) μg/d according to the FFQ-87 (forty-five food items containing lignans) and the FFQ-97 (sixty-five food items containing lignans), respectively. The mean concentration of serum Enterolactone was 23·2 ( sd 15·4) nmol/l. The adjusted Pearson's correlation between dietary intake of lignans assessed by the FFQ-97 and serum Enterolactone was statistically significant ( r 0·22, P = 0·01). No significant correlation was observed for the FFQ-87 ( r 0·09, P = 0·30). The present study indicates that the FFQ-97 might be better than the FFQ-87 for assessing dietary intake of lignans, although the correlation was low.

  • a probiotic mixture including galactooligosaccharides decreases fecal β glucosidase activity but does not affect serum Enterolactone concentration in men during a two week intervention
    Journal of Nutrition, 2011
    Co-Authors: Riina A Kekkonen, Herman Adlercreutz, Reetta Holma, Katja Hatakka, Tarja Suomalainen, Tuija Poussa, Riitta Korpela
    Abstract:

    A high serum concentration of Enterolactone, an enterolignan produced by colonic microbiota from precursors in cereals, vegetables, and fruits, is associated with reduced risk of acute coronary events. Probiotics and prebiotics modify colonic metabolism and may affect the serum Enterolactone concentration. The effects of a probiotic mixture alone and with galacto-oligosaccharides (GOS) on serum Enterolactone concentration and fecal metabolism were investigated in 18 healthy men. Participants received 3 interventions, each for 2 wk: 1) probiotics [Lactobacillus rhamnosus strains GG (LGG) and LC705, Propionibacterium freudenreichii ssp. shermanii JS, and Bifidobacterium breve Bb99, for a total amount of 2 x 10 10 CFU/d]; 2) probiotics and GOS 3.8 g/d; 3) probiotics, GOS, and rye bread (minimum 120 g/d). Serum Enterolactone and fecal dry weight, enzyme activities, pH, SCFA, lactic acid bacteria, bifidobacteria, propionibacteria, and the strains LGG and LC705 were determined. The serum Enterolactone concentration (nmot/L) tended to be decreased from baseline [mean (95% CI) 18.6(10.8― 26.4)] by probiotics alone [15.2 (7.8―22.7); P=0.095], was not significantly affected by probiotics with GOS [21.5 (13.2-29.8)], and was increased by probiotics with GOS and rye bread [24.6 (15.4―33.7); P < 0.05]. Probiotics alone did not affect fecal β-glucosidase activity and bifidobacteria, but probiotics with GOS decreased β-glucosidase activity and increased bifidobacteria compared with baseline (P< 0.05) and with probiotics alone (P< 0.01). In conclusion, this probiotic mixture with or without GOS does not significantly affect serum Enterolactone concentration. Because probiotics with GOS decreased fecal β-glucosidase activity but not serum Enterolactone, the reduced fecal β-glucosidase, within the range of activities measured, does not seem to limit the formation of Enterolactone.

Anja Olsen - One of the best experts on this subject based on the ideXlab platform.

  • prediagnosis plasma concentrations of Enterolactone and survival after colorectal cancer the danish diet cancer and health cohort
    British Journal of Nutrition, 2019
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Marianne Holm, Anja Olsen
    Abstract:

    The association between lifestyle and survival after colorectal cancer has received limited attention. The female sex hormone, oestrogen, has been associated with lower colorectal cancer risk and mortality after colorectal cancer. Phyto-oestrogens are plant compounds with structure similar to oestrogen, and the main sources in Western populations are plant lignans. We investigated the association between the main lignan metabolite, Enterolactone and survival after colorectal cancer among participants in the Danish Diet, Cancer and Health cohort. Prediagnosis plasma samples and lifestyle data, and clinical data from time of diagnosis from 416 women and 537 men diagnosed with colorectal cancer were used. Enterolactone was measured in plasma using a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. Participants were followed from date of diagnosis until death or end of follow-up. During this time, 210 women and 325 men died (170 women and 215 men died due to colorectal cancer). The Cox proportional hazards model was used to estimate hazard ratios (HR) and 95 % CI. Enterolactone concentrations were associated with lower colorectal cancer-specific mortality among women (HR per doubling : 0·88, 95 % CI 0·80, 0·97, P =0·0123). For men, on the contrary, Enterolactone concentrations were associated with higher colorectal cancer-specific mortality (HR per doubling : 1·10, 95 % CI 1·01, 1·21, P =0·0379). The use of antibiotics affects Enterolactone production, and the associations between higher Enterolactone and lower colorectal cancer-specific mortality were more pronounced among women who did not use antibiotics (analysis on a subset). Our results suggest that Enterolactone is associated with lower risk of mortality among women, but the opposite association was found among men.

  • pre diagnostic plasma Enterolactone concentrations are associated with lower mortality among individuals with type 2 diabetes a case cohort study in the danish diet cancer and health cohort
    Diabetologia, 2019
    Co-Authors: Anne K Eriksen, Knud Erik Bach Knudsen, Rikard Landberg, Natalja P Norskov, Cecilie Kyro, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Anja Olsen
    Abstract:

    Aims/hypothesis: The phytoestrogen Enterolactone is a gut microbiota-derived metabolite of plant lignans with suggested beneficial properties for health. In the current study, we investigated the association between pre-diagnostic plasma Enterolactone concentrations and mortality among individuals diagnosed with type 2 diabetes. Methods: In a population of people diagnosed with diabetes, nested within the Danish Diet, Cancer and Health cohort, we conducted a case-cohort study including a random sample of n = 450 cases (deceased) and a randomly selected subcohort of n = 850 (in total n = 617 deaths). Information on diagnosis, vital status and cause of death was obtained from Danish registers. Cox proportional hazard models with special weighting were applied to assess all-cause and cause-specific mortality. Results: The median Enterolactone concentration of the current population was low, 10.9 nmol/l (5th percentile to 95th percentile: 1.3–59.6), compared with previously reported concentrations from the Diet, Cancer and Health cohort. Pre-diagnostic Enterolactone concentrations were associated with lower all-cause mortality when assessed linearly per doubling in concentration (log 2 ) (HR 0.91 [95% CI 0.85, 0.96]) and according to quartiles (HR 0.63 [95% CI 0.48, 0.84]) for the highest quartile of Enterolactone compared with the lowest quartile. For cause-specific mortality, only death from diabetes (registered as underlying cause of death) reached statistical significance. Conclusions/interpretation: Based on this large cohort of people with diabetes with detailed and complete baseline and follow-up information, pre-diagnostic Enterolactone concentrations were inversely associated with mortality. To our knowledge, this is the first study on Enterolactone and type 2 diabetes mortality. Our findings call for further exploration of Enterolactone in type 2 diabetes management.

  • pre diagnostic plasma Enterolactone concentrations and breast cancer prognosis among postmenopausal women the danish diet cancer and health cohort
    Clinical Nutrition, 2017
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Anne K Eriksen, Kirsten Frederiksen, Marianne Holm, Louise Hansen, Anja Olsen
    Abstract:

    Summary Background & aims High intakes of the phytoestrogen lignans and high blood concentrations of its main biomarker, Enterolactone, has been associated with a better breast cancer prognosis. We investigated the association between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis (i.e. recurrence, breast cancer-specific mortality and all-cause mortality). Methods Plasma and data was available from the Danish Diet, Cancer and Health cohort. Information on treatment and clinical characteristics from registries and clinical databases and both pre-diagnostic and diagnostic plasma measurement of Enterolactone on a sub-set. Enterolactone was quantified in plasma using a high-throughput LC−MS/MS method. We followed 1457 breast cancer cases from date of diagnosis and until censoring or end-of-follow-up (median 9 years), during this time 404 died (250 of breast cancer) and 267 experienced recurrence. Cox proportional hazards models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Results Plasma Enterolactone were borderline significantly associated with lower breast cancer-specific mortality (HRdoubling = 0.93, 95% CI:0.86, 1.00, P = 0.0501), but not associated with all-cause mortality (HRdoubling = 0.95, 95% CI:0.89, 1.01) and recurrence (HRdoubling = 0.96, 95% CI: 0.89, 1.04) in the models adjusted for smoking, schooling, BMI, physical activity and use of menopausal hormones. Adjusting further for clinical characteristics and treatment did not change the results considerably. In the sensitivity analyses, an inverse association was found with all-cause and breast cancer-specific mortality for those where blood was collected ≤5 years before diagnosis. Conclusions Overall, no clear association was found between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis.

  • high throughput technique targeted lc ms ms method to measure Enterolactone a biomarker of healthy lifestyle for epidemiological investigation and clinical diagnosis
    The 1st International Electronic Conference on Metabolomics, 2016
    Co-Authors: Natalja P Norskov, Cecilie Kyro, Anja Olsen, Anne Tjonneland, Knud Erik Bach Knudsen
    Abstract:

    Opposite to untargeted metabolomics, targeted metabolomics approach can be applied when the biomarker is known. Enterolactone is a biomarker of healthy lifestyle and therefore used in epidemiological studies in revers association to lifestyle diseases such as type 2 diabetes, cardiovascular diseases and some forms of cancer. However, the analytical techniques to measure Enterolactone in plasma developed so far are based on the hydrolysis of Enterolactone with enzymes β-glucuronidase/sulfatese prior to the measurements and therefore are time consuming. Our purpose was to develop method that was rapid, reproducible, sensitive and easy to perform. Moreover, we wanted to develop a method to quantify Enterolactone in its intact form as glucuronide, sulfate and free Enterolactone. Tandem mass spectrometry (LC-MS/MS) was the method of choice due to its superior selectivity and sensitivity. Using the authentic standards of enterolacrone, Enterolactone glucuronide, and Enterolactone sulfate we developed the method that has shown good accuracy and precision at low concentration and high sensitivity, with LLOQ for Enterolactone sulfate at 16 pM, Enterolactone glucuronide at 26 pM and free Enterolactone at 86 pM. The method was validated with blank human plasma and applied to measure 3956 plasma samples from an epidemiological study. The results of Principal Component Analyses (PCA) indicated that the total concentration of Enterolactone and the concentration of Enterolactone glucuronide and sulfate negatively correlated to BMI, age, ratio, cancer type, smoking status and alcohol intake but positively to sport, fruits-, vegetables- and whole-grain intake. Moreover, we found Enterolactone glucuronide to be the major conjugation form and that there was no difference between men and women. The importance of this novel, targeted LC-MS/MS method is two-fold. Firstly, we hope that measuring Enterolactone in its intact forms will contribute with new knowledge on the role of Enterolactone in human health. Secondly, since the method is rapid and easy to perform it can be used for high-throughput of samples and therefore will be the method of choice for future epidemiological investigations and clinical diagnosis.

  • High-throughput technique – targeted LC-MS/MS method to measure Enterolactone "a biomarker of healthy lifestyle" for epidemiological investigation and clinical diagnosis
    Proceedings of The 1st International Electronic Conference on Metabolomics, 2016
    Co-Authors: Natalja P Norskov, Cecilie Kyro, Anja Olsen, Anne Tjonneland, Knud Erik Bach Knudsen
    Abstract:

    Opposite to untargeted metabolomics, targeted metabolomics approach can be applied when the biomarker is known. Enterolactone is a biomarker of healthy lifestyle and therefore used in epidemiological studies in revers association to lifestyle diseases such as type 2 diabetes, cardiovascular diseases and some forms of cancer. However, the analytical techniques to measure Enterolactone in plasma developed so far are based on the hydrolysis of Enterolactone with enzymes β-glucuronidase/sulfatese prior to the measurements and therefore are time consuming. Our purpose was to develop method that was rapid, reproducible, sensitive and easy to perform. Moreover, we wanted to develop a method to quantify Enterolactone in its intact form as glucuronide, sulfate and free Enterolactone. Tandem mass spectrometry (LC-MS/MS) was the method of choice due to its superior selectivity and sensitivity. Using the authentic standards of enterolacrone, Enterolactone glucuronide, and Enterolactone sulfate we developed the method that has shown good accuracy and precision at low concentration and high sensitivity, with LLOQ for Enterolactone sulfate at 16 pM, Enterolactone glucuronide at 26 pM and free Enterolactone at 86 pM. The method was validated with blank human plasma and applied to measure 3956 plasma samples from an epidemiological study. The results of Principal Component Analyses (PCA) indicated that the total concentration of Enterolactone and the concentration of Enterolactone glucuronide and sulfate negatively correlated to BMI, age, ratio, cancer type, smoking status and alcohol intake but positively to sport, fruits-, vegetables- and whole-grain intake. Moreover, we found Enterolactone glucuronide to be the major conjugation form and that there was no difference between men and women. The importance of this novel, targeted LC-MS/MS method is two-fold. Firstly, we hope that measuring Enterolactone in its intact forms will contribute with new knowledge on the role of Enterolactone in human health. Secondly, since the method is rapid and easy to perform it can be used for high-throughput of samples and therefore will be the method of choice for future epidemiological investigations and clinical diagnosis.

Anne Tjonneland - One of the best experts on this subject based on the ideXlab platform.

  • prediagnosis plasma concentrations of Enterolactone and survival after colorectal cancer the danish diet cancer and health cohort
    British Journal of Nutrition, 2019
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Marianne Holm, Anja Olsen
    Abstract:

    The association between lifestyle and survival after colorectal cancer has received limited attention. The female sex hormone, oestrogen, has been associated with lower colorectal cancer risk and mortality after colorectal cancer. Phyto-oestrogens are plant compounds with structure similar to oestrogen, and the main sources in Western populations are plant lignans. We investigated the association between the main lignan metabolite, Enterolactone and survival after colorectal cancer among participants in the Danish Diet, Cancer and Health cohort. Prediagnosis plasma samples and lifestyle data, and clinical data from time of diagnosis from 416 women and 537 men diagnosed with colorectal cancer were used. Enterolactone was measured in plasma using a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. Participants were followed from date of diagnosis until death or end of follow-up. During this time, 210 women and 325 men died (170 women and 215 men died due to colorectal cancer). The Cox proportional hazards model was used to estimate hazard ratios (HR) and 95 % CI. Enterolactone concentrations were associated with lower colorectal cancer-specific mortality among women (HR per doubling : 0·88, 95 % CI 0·80, 0·97, P =0·0123). For men, on the contrary, Enterolactone concentrations were associated with higher colorectal cancer-specific mortality (HR per doubling : 1·10, 95 % CI 1·01, 1·21, P =0·0379). The use of antibiotics affects Enterolactone production, and the associations between higher Enterolactone and lower colorectal cancer-specific mortality were more pronounced among women who did not use antibiotics (analysis on a subset). Our results suggest that Enterolactone is associated with lower risk of mortality among women, but the opposite association was found among men.

  • pre diagnostic plasma Enterolactone concentrations are associated with lower mortality among individuals with type 2 diabetes a case cohort study in the danish diet cancer and health cohort
    Diabetologia, 2019
    Co-Authors: Anne K Eriksen, Knud Erik Bach Knudsen, Rikard Landberg, Natalja P Norskov, Cecilie Kyro, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Anja Olsen
    Abstract:

    Aims/hypothesis: The phytoestrogen Enterolactone is a gut microbiota-derived metabolite of plant lignans with suggested beneficial properties for health. In the current study, we investigated the association between pre-diagnostic plasma Enterolactone concentrations and mortality among individuals diagnosed with type 2 diabetes. Methods: In a population of people diagnosed with diabetes, nested within the Danish Diet, Cancer and Health cohort, we conducted a case-cohort study including a random sample of n = 450 cases (deceased) and a randomly selected subcohort of n = 850 (in total n = 617 deaths). Information on diagnosis, vital status and cause of death was obtained from Danish registers. Cox proportional hazard models with special weighting were applied to assess all-cause and cause-specific mortality. Results: The median Enterolactone concentration of the current population was low, 10.9 nmol/l (5th percentile to 95th percentile: 1.3–59.6), compared with previously reported concentrations from the Diet, Cancer and Health cohort. Pre-diagnostic Enterolactone concentrations were associated with lower all-cause mortality when assessed linearly per doubling in concentration (log 2 ) (HR 0.91 [95% CI 0.85, 0.96]) and according to quartiles (HR 0.63 [95% CI 0.48, 0.84]) for the highest quartile of Enterolactone compared with the lowest quartile. For cause-specific mortality, only death from diabetes (registered as underlying cause of death) reached statistical significance. Conclusions/interpretation: Based on this large cohort of people with diabetes with detailed and complete baseline and follow-up information, pre-diagnostic Enterolactone concentrations were inversely associated with mortality. To our knowledge, this is the first study on Enterolactone and type 2 diabetes mortality. Our findings call for further exploration of Enterolactone in type 2 diabetes management.

  • pre diagnostic plasma Enterolactone concentrations and breast cancer prognosis among postmenopausal women the danish diet cancer and health cohort
    Clinical Nutrition, 2017
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Anne K Eriksen, Kirsten Frederiksen, Marianne Holm, Louise Hansen, Anja Olsen
    Abstract:

    Summary Background & aims High intakes of the phytoestrogen lignans and high blood concentrations of its main biomarker, Enterolactone, has been associated with a better breast cancer prognosis. We investigated the association between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis (i.e. recurrence, breast cancer-specific mortality and all-cause mortality). Methods Plasma and data was available from the Danish Diet, Cancer and Health cohort. Information on treatment and clinical characteristics from registries and clinical databases and both pre-diagnostic and diagnostic plasma measurement of Enterolactone on a sub-set. Enterolactone was quantified in plasma using a high-throughput LC−MS/MS method. We followed 1457 breast cancer cases from date of diagnosis and until censoring or end-of-follow-up (median 9 years), during this time 404 died (250 of breast cancer) and 267 experienced recurrence. Cox proportional hazards models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Results Plasma Enterolactone were borderline significantly associated with lower breast cancer-specific mortality (HRdoubling = 0.93, 95% CI:0.86, 1.00, P = 0.0501), but not associated with all-cause mortality (HRdoubling = 0.95, 95% CI:0.89, 1.01) and recurrence (HRdoubling = 0.96, 95% CI: 0.89, 1.04) in the models adjusted for smoking, schooling, BMI, physical activity and use of menopausal hormones. Adjusting further for clinical characteristics and treatment did not change the results considerably. In the sensitivity analyses, an inverse association was found with all-cause and breast cancer-specific mortality for those where blood was collected ≤5 years before diagnosis. Conclusions Overall, no clear association was found between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis.

  • prediagnostic Enterolactone concentrations and mortality among danish men diagnosed with prostate cancer
    European Journal of Clinical Nutrition, 2017
    Co-Authors: Anne K Eriksen, Rikard Landberg, Natalja P Norskov, Cecilie Kyro, Anne Tjonneland, Anne Katrine Bolvig, Jane Christensen, Kim Overvad, A Olsen
    Abstract:

    BACKGROUND/OBJECTIVES: Evidence on the role of diet in relation to prostate cancer progression is sparse. Foods rich in lignans have shown beneficial effects on prostate cancer progression in both animal studies and small human intervention studies, including beneficial effects on prostate-specific antigen levels and tumour growth. The lignan metabolite, Enterolactone, has further shown to slow prostate cancer cell growth in vitro. The aim was to investigate the association between prediagnostic Enterolactone concentrations and mortality among men with prostate cancer. SSUBLJECTS/METHODS: Prediagnostic plasma concentrations of Enterolactone from 1390 men diagnosed with prostate cancer from the Danish Diet, Cancer and Health cohort were related to all-cause or prostate cancer-specific death, using Cox proportional hazards models with follow-up time (from the date of diagnose until the date of death, emigration or end of follow-up by December 2013) as the underlying time axis. RESULTS: The hazard ratios for Enterolactone concentrations assessed linearly by 20 nmol/l increments was 0.95 (0.90, 1.02) for all-cause mortality and 0.98 (0.92, 1.05) for prostate cancer-specific mortality. Categorisation of Enterolactone concentrations into quartiles did not reveal a different pattern. No effect modifications by smoking, body mass index or sport were observed, and the associations did not differ by prostate cancer aggressiveness. CONCLUSIONS: We found no association between Enterolactone concentrations and mortality among men diagnosed with prostate cancer.

  • high throughput technique targeted lc ms ms method to measure Enterolactone a biomarker of healthy lifestyle for epidemiological investigation and clinical diagnosis
    The 1st International Electronic Conference on Metabolomics, 2016
    Co-Authors: Natalja P Norskov, Cecilie Kyro, Anja Olsen, Anne Tjonneland, Knud Erik Bach Knudsen
    Abstract:

    Opposite to untargeted metabolomics, targeted metabolomics approach can be applied when the biomarker is known. Enterolactone is a biomarker of healthy lifestyle and therefore used in epidemiological studies in revers association to lifestyle diseases such as type 2 diabetes, cardiovascular diseases and some forms of cancer. However, the analytical techniques to measure Enterolactone in plasma developed so far are based on the hydrolysis of Enterolactone with enzymes β-glucuronidase/sulfatese prior to the measurements and therefore are time consuming. Our purpose was to develop method that was rapid, reproducible, sensitive and easy to perform. Moreover, we wanted to develop a method to quantify Enterolactone in its intact form as glucuronide, sulfate and free Enterolactone. Tandem mass spectrometry (LC-MS/MS) was the method of choice due to its superior selectivity and sensitivity. Using the authentic standards of enterolacrone, Enterolactone glucuronide, and Enterolactone sulfate we developed the method that has shown good accuracy and precision at low concentration and high sensitivity, with LLOQ for Enterolactone sulfate at 16 pM, Enterolactone glucuronide at 26 pM and free Enterolactone at 86 pM. The method was validated with blank human plasma and applied to measure 3956 plasma samples from an epidemiological study. The results of Principal Component Analyses (PCA) indicated that the total concentration of Enterolactone and the concentration of Enterolactone glucuronide and sulfate negatively correlated to BMI, age, ratio, cancer type, smoking status and alcohol intake but positively to sport, fruits-, vegetables- and whole-grain intake. Moreover, we found Enterolactone glucuronide to be the major conjugation form and that there was no difference between men and women. The importance of this novel, targeted LC-MS/MS method is two-fold. Firstly, we hope that measuring Enterolactone in its intact forms will contribute with new knowledge on the role of Enterolactone in human health. Secondly, since the method is rapid and easy to perform it can be used for high-throughput of samples and therefore will be the method of choice for future epidemiological investigations and clinical diagnosis.

Knud Erik Bach Knudsen - One of the best experts on this subject based on the ideXlab platform.

  • prediagnosis plasma concentrations of Enterolactone and survival after colorectal cancer the danish diet cancer and health cohort
    British Journal of Nutrition, 2019
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Marianne Holm, Anja Olsen
    Abstract:

    The association between lifestyle and survival after colorectal cancer has received limited attention. The female sex hormone, oestrogen, has been associated with lower colorectal cancer risk and mortality after colorectal cancer. Phyto-oestrogens are plant compounds with structure similar to oestrogen, and the main sources in Western populations are plant lignans. We investigated the association between the main lignan metabolite, Enterolactone and survival after colorectal cancer among participants in the Danish Diet, Cancer and Health cohort. Prediagnosis plasma samples and lifestyle data, and clinical data from time of diagnosis from 416 women and 537 men diagnosed with colorectal cancer were used. Enterolactone was measured in plasma using a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. Participants were followed from date of diagnosis until death or end of follow-up. During this time, 210 women and 325 men died (170 women and 215 men died due to colorectal cancer). The Cox proportional hazards model was used to estimate hazard ratios (HR) and 95 % CI. Enterolactone concentrations were associated with lower colorectal cancer-specific mortality among women (HR per doubling : 0·88, 95 % CI 0·80, 0·97, P =0·0123). For men, on the contrary, Enterolactone concentrations were associated with higher colorectal cancer-specific mortality (HR per doubling : 1·10, 95 % CI 1·01, 1·21, P =0·0379). The use of antibiotics affects Enterolactone production, and the associations between higher Enterolactone and lower colorectal cancer-specific mortality were more pronounced among women who did not use antibiotics (analysis on a subset). Our results suggest that Enterolactone is associated with lower risk of mortality among women, but the opposite association was found among men.

  • Serum Enterolactone concentrations are low in colon but not in rectal cancer patients
    Scientific Reports, 2019
    Co-Authors: Anne Tuomisto, Knud Erik Bach Knudsen, Natalja P Norskov, Paivi Sirnio, Juha P Vayrynen, Shivaprakash Jagalur Mutt, Kai Klintrup, Jyrki Mäkelä, Markus J. Mäkinen, Karl-heinz Herzig
    Abstract:

    The dietary lignan metabolite, Enterolactone, has been suggested to have anti-cancer functions, and high serum Enterolactone concentrations have been associated with decreased risk of breast and prostate cancers. We hypothesized that serum Enterolactone concentrations as a marker of plant-based foods are associated with decreased risk in colorectal cancer (CRC). We measured serum Enterolactone glucuronide and sulfate concentrations by liquid chromatography-tandem mass spectrometry in 115 CRC patients and 76 sex- and age-matched controls and analyzed the results with respect to tumor parameters, clinical parameters, and systemic inflammatory markers. Patients with colon cancer had significant lower serum Enterolactone glucuronide and sulfate concentrations than controls (glucuronide: median 3.14 nM vs. 6.32 nM, P 

  • pre diagnostic plasma Enterolactone concentrations are associated with lower mortality among individuals with type 2 diabetes a case cohort study in the danish diet cancer and health cohort
    Diabetologia, 2019
    Co-Authors: Anne K Eriksen, Knud Erik Bach Knudsen, Rikard Landberg, Natalja P Norskov, Cecilie Kyro, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Anja Olsen
    Abstract:

    Aims/hypothesis: The phytoestrogen Enterolactone is a gut microbiota-derived metabolite of plant lignans with suggested beneficial properties for health. In the current study, we investigated the association between pre-diagnostic plasma Enterolactone concentrations and mortality among individuals diagnosed with type 2 diabetes. Methods: In a population of people diagnosed with diabetes, nested within the Danish Diet, Cancer and Health cohort, we conducted a case-cohort study including a random sample of n = 450 cases (deceased) and a randomly selected subcohort of n = 850 (in total n = 617 deaths). Information on diagnosis, vital status and cause of death was obtained from Danish registers. Cox proportional hazard models with special weighting were applied to assess all-cause and cause-specific mortality. Results: The median Enterolactone concentration of the current population was low, 10.9 nmol/l (5th percentile to 95th percentile: 1.3–59.6), compared with previously reported concentrations from the Diet, Cancer and Health cohort. Pre-diagnostic Enterolactone concentrations were associated with lower all-cause mortality when assessed linearly per doubling in concentration (log 2 ) (HR 0.91 [95% CI 0.85, 0.96]) and according to quartiles (HR 0.63 [95% CI 0.48, 0.84]) for the highest quartile of Enterolactone compared with the lowest quartile. For cause-specific mortality, only death from diabetes (registered as underlying cause of death) reached statistical significance. Conclusions/interpretation: Based on this large cohort of people with diabetes with detailed and complete baseline and follow-up information, pre-diagnostic Enterolactone concentrations were inversely associated with mortality. To our knowledge, this is the first study on Enterolactone and type 2 diabetes mortality. Our findings call for further exploration of Enterolactone in type 2 diabetes management.

  • pre diagnostic plasma Enterolactone concentrations and breast cancer prognosis among postmenopausal women the danish diet cancer and health cohort
    Clinical Nutrition, 2017
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Anne K Eriksen, Kirsten Frederiksen, Marianne Holm, Louise Hansen, Anja Olsen
    Abstract:

    Summary Background & aims High intakes of the phytoestrogen lignans and high blood concentrations of its main biomarker, Enterolactone, has been associated with a better breast cancer prognosis. We investigated the association between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis (i.e. recurrence, breast cancer-specific mortality and all-cause mortality). Methods Plasma and data was available from the Danish Diet, Cancer and Health cohort. Information on treatment and clinical characteristics from registries and clinical databases and both pre-diagnostic and diagnostic plasma measurement of Enterolactone on a sub-set. Enterolactone was quantified in plasma using a high-throughput LC−MS/MS method. We followed 1457 breast cancer cases from date of diagnosis and until censoring or end-of-follow-up (median 9 years), during this time 404 died (250 of breast cancer) and 267 experienced recurrence. Cox proportional hazards models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Results Plasma Enterolactone were borderline significantly associated with lower breast cancer-specific mortality (HRdoubling = 0.93, 95% CI:0.86, 1.00, P = 0.0501), but not associated with all-cause mortality (HRdoubling = 0.95, 95% CI:0.89, 1.01) and recurrence (HRdoubling = 0.96, 95% CI: 0.89, 1.04) in the models adjusted for smoking, schooling, BMI, physical activity and use of menopausal hormones. Adjusting further for clinical characteristics and treatment did not change the results considerably. In the sensitivity analyses, an inverse association was found with all-cause and breast cancer-specific mortality for those where blood was collected ≤5 years before diagnosis. Conclusions Overall, no clear association was found between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis.

  • high throughput technique targeted lc ms ms method to measure Enterolactone a biomarker of healthy lifestyle for epidemiological investigation and clinical diagnosis
    The 1st International Electronic Conference on Metabolomics, 2016
    Co-Authors: Natalja P Norskov, Cecilie Kyro, Anja Olsen, Anne Tjonneland, Knud Erik Bach Knudsen
    Abstract:

    Opposite to untargeted metabolomics, targeted metabolomics approach can be applied when the biomarker is known. Enterolactone is a biomarker of healthy lifestyle and therefore used in epidemiological studies in revers association to lifestyle diseases such as type 2 diabetes, cardiovascular diseases and some forms of cancer. However, the analytical techniques to measure Enterolactone in plasma developed so far are based on the hydrolysis of Enterolactone with enzymes β-glucuronidase/sulfatese prior to the measurements and therefore are time consuming. Our purpose was to develop method that was rapid, reproducible, sensitive and easy to perform. Moreover, we wanted to develop a method to quantify Enterolactone in its intact form as glucuronide, sulfate and free Enterolactone. Tandem mass spectrometry (LC-MS/MS) was the method of choice due to its superior selectivity and sensitivity. Using the authentic standards of enterolacrone, Enterolactone glucuronide, and Enterolactone sulfate we developed the method that has shown good accuracy and precision at low concentration and high sensitivity, with LLOQ for Enterolactone sulfate at 16 pM, Enterolactone glucuronide at 26 pM and free Enterolactone at 86 pM. The method was validated with blank human plasma and applied to measure 3956 plasma samples from an epidemiological study. The results of Principal Component Analyses (PCA) indicated that the total concentration of Enterolactone and the concentration of Enterolactone glucuronide and sulfate negatively correlated to BMI, age, ratio, cancer type, smoking status and alcohol intake but positively to sport, fruits-, vegetables- and whole-grain intake. Moreover, we found Enterolactone glucuronide to be the major conjugation form and that there was no difference between men and women. The importance of this novel, targeted LC-MS/MS method is two-fold. Firstly, we hope that measuring Enterolactone in its intact forms will contribute with new knowledge on the role of Enterolactone in human health. Secondly, since the method is rapid and easy to perform it can be used for high-throughput of samples and therefore will be the method of choice for future epidemiological investigations and clinical diagnosis.

Cecilie Kyro - One of the best experts on this subject based on the ideXlab platform.

  • prediagnosis plasma concentrations of Enterolactone and survival after colorectal cancer the danish diet cancer and health cohort
    British Journal of Nutrition, 2019
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Marianne Holm, Anja Olsen
    Abstract:

    The association between lifestyle and survival after colorectal cancer has received limited attention. The female sex hormone, oestrogen, has been associated with lower colorectal cancer risk and mortality after colorectal cancer. Phyto-oestrogens are plant compounds with structure similar to oestrogen, and the main sources in Western populations are plant lignans. We investigated the association between the main lignan metabolite, Enterolactone and survival after colorectal cancer among participants in the Danish Diet, Cancer and Health cohort. Prediagnosis plasma samples and lifestyle data, and clinical data from time of diagnosis from 416 women and 537 men diagnosed with colorectal cancer were used. Enterolactone was measured in plasma using a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. Participants were followed from date of diagnosis until death or end of follow-up. During this time, 210 women and 325 men died (170 women and 215 men died due to colorectal cancer). The Cox proportional hazards model was used to estimate hazard ratios (HR) and 95 % CI. Enterolactone concentrations were associated with lower colorectal cancer-specific mortality among women (HR per doubling : 0·88, 95 % CI 0·80, 0·97, P =0·0123). For men, on the contrary, Enterolactone concentrations were associated with higher colorectal cancer-specific mortality (HR per doubling : 1·10, 95 % CI 1·01, 1·21, P =0·0379). The use of antibiotics affects Enterolactone production, and the associations between higher Enterolactone and lower colorectal cancer-specific mortality were more pronounced among women who did not use antibiotics (analysis on a subset). Our results suggest that Enterolactone is associated with lower risk of mortality among women, but the opposite association was found among men.

  • pre diagnostic plasma Enterolactone concentrations are associated with lower mortality among individuals with type 2 diabetes a case cohort study in the danish diet cancer and health cohort
    Diabetologia, 2019
    Co-Authors: Anne K Eriksen, Knud Erik Bach Knudsen, Rikard Landberg, Natalja P Norskov, Cecilie Kyro, Anne Tjonneland, Kim Overvad, Kirsten Frederiksen, Anja Olsen
    Abstract:

    Aims/hypothesis: The phytoestrogen Enterolactone is a gut microbiota-derived metabolite of plant lignans with suggested beneficial properties for health. In the current study, we investigated the association between pre-diagnostic plasma Enterolactone concentrations and mortality among individuals diagnosed with type 2 diabetes. Methods: In a population of people diagnosed with diabetes, nested within the Danish Diet, Cancer and Health cohort, we conducted a case-cohort study including a random sample of n = 450 cases (deceased) and a randomly selected subcohort of n = 850 (in total n = 617 deaths). Information on diagnosis, vital status and cause of death was obtained from Danish registers. Cox proportional hazard models with special weighting were applied to assess all-cause and cause-specific mortality. Results: The median Enterolactone concentration of the current population was low, 10.9 nmol/l (5th percentile to 95th percentile: 1.3–59.6), compared with previously reported concentrations from the Diet, Cancer and Health cohort. Pre-diagnostic Enterolactone concentrations were associated with lower all-cause mortality when assessed linearly per doubling in concentration (log 2 ) (HR 0.91 [95% CI 0.85, 0.96]) and according to quartiles (HR 0.63 [95% CI 0.48, 0.84]) for the highest quartile of Enterolactone compared with the lowest quartile. For cause-specific mortality, only death from diabetes (registered as underlying cause of death) reached statistical significance. Conclusions/interpretation: Based on this large cohort of people with diabetes with detailed and complete baseline and follow-up information, pre-diagnostic Enterolactone concentrations were inversely associated with mortality. To our knowledge, this is the first study on Enterolactone and type 2 diabetes mortality. Our findings call for further exploration of Enterolactone in type 2 diabetes management.

  • pre diagnostic plasma Enterolactone concentrations and breast cancer prognosis among postmenopausal women the danish diet cancer and health cohort
    Clinical Nutrition, 2017
    Co-Authors: Cecilie Kyro, Knud Erik Bach Knudsen, Natalja P Norskov, Anne Tjonneland, Anne K Eriksen, Kirsten Frederiksen, Marianne Holm, Louise Hansen, Anja Olsen
    Abstract:

    Summary Background & aims High intakes of the phytoestrogen lignans and high blood concentrations of its main biomarker, Enterolactone, has been associated with a better breast cancer prognosis. We investigated the association between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis (i.e. recurrence, breast cancer-specific mortality and all-cause mortality). Methods Plasma and data was available from the Danish Diet, Cancer and Health cohort. Information on treatment and clinical characteristics from registries and clinical databases and both pre-diagnostic and diagnostic plasma measurement of Enterolactone on a sub-set. Enterolactone was quantified in plasma using a high-throughput LC−MS/MS method. We followed 1457 breast cancer cases from date of diagnosis and until censoring or end-of-follow-up (median 9 years), during this time 404 died (250 of breast cancer) and 267 experienced recurrence. Cox proportional hazards models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Results Plasma Enterolactone were borderline significantly associated with lower breast cancer-specific mortality (HRdoubling = 0.93, 95% CI:0.86, 1.00, P = 0.0501), but not associated with all-cause mortality (HRdoubling = 0.95, 95% CI:0.89, 1.01) and recurrence (HRdoubling = 0.96, 95% CI: 0.89, 1.04) in the models adjusted for smoking, schooling, BMI, physical activity and use of menopausal hormones. Adjusting further for clinical characteristics and treatment did not change the results considerably. In the sensitivity analyses, an inverse association was found with all-cause and breast cancer-specific mortality for those where blood was collected ≤5 years before diagnosis. Conclusions Overall, no clear association was found between pre-diagnostic plasma concentrations of Enterolactone and breast cancer prognosis.

  • prediagnostic Enterolactone concentrations and mortality among danish men diagnosed with prostate cancer
    European Journal of Clinical Nutrition, 2017
    Co-Authors: Anne K Eriksen, Rikard Landberg, Natalja P Norskov, Cecilie Kyro, Anne Tjonneland, Anne Katrine Bolvig, Jane Christensen, Kim Overvad, A Olsen
    Abstract:

    BACKGROUND/OBJECTIVES: Evidence on the role of diet in relation to prostate cancer progression is sparse. Foods rich in lignans have shown beneficial effects on prostate cancer progression in both animal studies and small human intervention studies, including beneficial effects on prostate-specific antigen levels and tumour growth. The lignan metabolite, Enterolactone, has further shown to slow prostate cancer cell growth in vitro. The aim was to investigate the association between prediagnostic Enterolactone concentrations and mortality among men with prostate cancer. SSUBLJECTS/METHODS: Prediagnostic plasma concentrations of Enterolactone from 1390 men diagnosed with prostate cancer from the Danish Diet, Cancer and Health cohort were related to all-cause or prostate cancer-specific death, using Cox proportional hazards models with follow-up time (from the date of diagnose until the date of death, emigration or end of follow-up by December 2013) as the underlying time axis. RESULTS: The hazard ratios for Enterolactone concentrations assessed linearly by 20 nmol/l increments was 0.95 (0.90, 1.02) for all-cause mortality and 0.98 (0.92, 1.05) for prostate cancer-specific mortality. Categorisation of Enterolactone concentrations into quartiles did not reveal a different pattern. No effect modifications by smoking, body mass index or sport were observed, and the associations did not differ by prostate cancer aggressiveness. CONCLUSIONS: We found no association between Enterolactone concentrations and mortality among men diagnosed with prostate cancer.

  • high throughput technique targeted lc ms ms method to measure Enterolactone a biomarker of healthy lifestyle for epidemiological investigation and clinical diagnosis
    The 1st International Electronic Conference on Metabolomics, 2016
    Co-Authors: Natalja P Norskov, Cecilie Kyro, Anja Olsen, Anne Tjonneland, Knud Erik Bach Knudsen
    Abstract:

    Opposite to untargeted metabolomics, targeted metabolomics approach can be applied when the biomarker is known. Enterolactone is a biomarker of healthy lifestyle and therefore used in epidemiological studies in revers association to lifestyle diseases such as type 2 diabetes, cardiovascular diseases and some forms of cancer. However, the analytical techniques to measure Enterolactone in plasma developed so far are based on the hydrolysis of Enterolactone with enzymes β-glucuronidase/sulfatese prior to the measurements and therefore are time consuming. Our purpose was to develop method that was rapid, reproducible, sensitive and easy to perform. Moreover, we wanted to develop a method to quantify Enterolactone in its intact form as glucuronide, sulfate and free Enterolactone. Tandem mass spectrometry (LC-MS/MS) was the method of choice due to its superior selectivity and sensitivity. Using the authentic standards of enterolacrone, Enterolactone glucuronide, and Enterolactone sulfate we developed the method that has shown good accuracy and precision at low concentration and high sensitivity, with LLOQ for Enterolactone sulfate at 16 pM, Enterolactone glucuronide at 26 pM and free Enterolactone at 86 pM. The method was validated with blank human plasma and applied to measure 3956 plasma samples from an epidemiological study. The results of Principal Component Analyses (PCA) indicated that the total concentration of Enterolactone and the concentration of Enterolactone glucuronide and sulfate negatively correlated to BMI, age, ratio, cancer type, smoking status and alcohol intake but positively to sport, fruits-, vegetables- and whole-grain intake. Moreover, we found Enterolactone glucuronide to be the major conjugation form and that there was no difference between men and women. The importance of this novel, targeted LC-MS/MS method is two-fold. Firstly, we hope that measuring Enterolactone in its intact forms will contribute with new knowledge on the role of Enterolactone in human health. Secondly, since the method is rapid and easy to perform it can be used for high-throughput of samples and therefore will be the method of choice for future epidemiological investigations and clinical diagnosis.